Categories: HealthcareNews

Media Alert: Lynx.MD Leveraged for Study on Infliximab Optimization for IBD to be Presented at Crohn’s & Colitis Congress

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

Study real-world outcomes of IBD infliximab patients with the Anser TDM Test: Presentation by Prometheus using the Lynx GI data library

PALO ALTO, CA / ACCESSWIRE / January 17, 2024 / Lynx.MD, a provider of a comprehensive medical data intelligence platform, is honored to support our partner, Andrew Shim, Medical Affairs, Prometheus Laboratories Inc, poster presentation at the upcoming Crohn’s & Colitis Congress 2024 demonstrating the potential of therapeutic drug monitoring (TDM) to positively impact patient outcome with infliximab dose optimization.

Poster Session: Comparing Real-World Outcomes… Using TDM vs. Unoptimized Control Group

Presenter: Dr. Andrew Shim, Prometheus Laboratories Inc., University of Minnesota

When: Friday, January 26th, 7:00 PM – 8:00 PM Pacific

Venue: Bellagio, Las Vegas

Key points of interest:

  • Large-scale study conducted in real-world community-based practices.
  • TDM-guided infliximab optimization linked to reduced rates of IBD-related surgery compared to standard dosing.
  • Findings add to growing evidence supporting personalized, TDM-driven treatment for improved outcomes and reduced healthcare costs.

This study was made possible through a powerful collaboration between Prometheus Laboratories Inc. and Lynx.MD, a leading real-world medical data platform. Leveraging Lynx.MD’s rich repository of de-identified clinical data within the Lynx.MD Trusted Data Environment, Prometheus researchers gained unparalleled access to real-world treatment patterns and outcomes in a diverse patient population. This unique partnership exemplifies the power of data-driven research in advancing personalized medicine and ultimately improving patient lives.

Don’t miss this opportunity to learn more about this potentially transformative approach to IBD care at the Crohn’s & Colitis Congress. Attend Dr. Shim’s presentation to discover how data-driven insights can inform IBD treatments.

Additional Information:

Contact:
Victoria Holl
Vp of Marketing
Lynx.MD
victoria@lynx.md
650-248-4262

SOURCE: Lynx MD

View the original press release on accesswire.com

Staff

Recent Posts

Avio Health Launches World’s First Functional Medicine LLM for Emagene Life, Transforming Personalized Healthcare

KUALA LUMPUR, Malaysia, June 27, 2025 /PRNewswire/ -- Avio Health, a deep-tech company dedicated to advancing healthcare through data analytics and machine learning, today announced…

3 hours ago

Challenge accepted: New funding for ambitious projects within biomanufacturing, cardiometabolic diseases, and artificial intelligence

The 2025 Novo Nordisk Foundation Challenge Programme awards DKK 479 million to nine innovative projects that…

3 hours ago

Vinamilk Showcases Science-Driven Innovation and Wins Prestigious Awards at Global Dairy Congress 2025

AMSTERDAM, June 26, 2025 /PRNewswire/ -- Vinamilk, Vietnam's leading dairy company, presented its science-driven innovation…

9 hours ago

Tariff Uncertainty Disrupts Healthcare Operations: New Diagnostic Survey Highlights Staffing Changes, Delayed Purchases, and Supply Chain Strain

ARLINGTON, Va., June 26, 2025 /PRNewswire/ -- A new survey of 195 diagnostic imaging and…

15 hours ago

Ultima Genomics Selected to Support the World’s Largest Proteomics Studies to Date Led by Regeneron Genetics Center

FREMONT, Calif., June 26, 2025 /PRNewswire/ -- Ultima Genomics, a developer of an innovative new…

15 hours ago